🔴 Outlook Therapeutics is trading 5.4% down with no clear company-specific catalyst identified

Outlook Therapeutics is trading 5.4% lower at $0.55 on October 13, 2026, with no clear company-specific catalyst identified. - Its latest identified release was an October 9 appointment of a chief commercial officer ahead of the planned LYTENAVA launch; no new event surfaced on October 13. - Biotech-sector weakness may be contributing: XBI was down 2.01%, while broader markets were nearly flat. Available evidence does not establish a direct cause for the larger decline.